[Renal cell carcinoma associated proteins. Isolation, cloning and immunogenicity evaluation].
Haferkamp
A
A
Urologische Klinik, Universitätsklinikum, Im Neuenheimer Feld 110, 69120 Heidelberg. Axel_Haferkamp@qmed.uni-heidelberg.de
Hohenfellner
M
M
Hautmann
R
R
Zöller
M
M
D000818:Animals; D000951:Antigens, Neoplasm / Q000235:genetics* / Q000276:immunology; D001402:B-Lymphocytes / Q000276:immunology; D014408:Biomarkers, Tumor / Q000235:genetics* / Q000276:immunology; D019496:Cancer Vaccines / Q000276:immunology / Q000627:therapeutic use; D002292:Carcinoma, Renal Cell / Q000235:genetics* / Q000276:immunology / Q000473:pathology; D003001:Cloning, Molecular; D018450:Disease Progression; D006801:Humans; D016219:Immunotherapy, Adoptive; D007680:Kidney Neoplasms / Q000235:genetics* / Q000276:immunology / Q000473:pathology; D051379:Mice; D016513:Mice, SCID; D020928:Mitogen-Activated Protein Kinases / Q000235:genetics / Q000276:immunology; D009367:Neoplasm Staging; D013602:T-Lymphocytes, Cytotoxic / Q000276:immunology; D019444:Vaccines, DNA / Q000276:immunology / Q000627:therapeutic use
D000951:Antigens, Neoplasm; D014408:Biomarkers, Tumor; D019496:Cancer Vaccines; C505356:MAGE-9 antigen, human; D019444:Vaccines, DNA; C498978:MOK protein, human; D020928:Mitogen-Activated Protein Kinases